Scientists have identified a compound in black licorice that appears capable of protecting intestinal cells from damage linked to inflammatory bowel disease, opening a new research avenue for the millions of people who don't respond well to current treatments.
The discovery emerged from a stem cell study led by researchers at the University of Tokyo who screened thousands of compounds against an IBD-like condition in laboratory-grown human intestinal tissue. Glycyrrhizin, the naturally occurring ingredient behind licorice's distinctive taste, emerged as one of the most promising candidates.
IBD remains one of medicine's stubborn challenges. The chronic condition, which strikes roughly 4 million people worldwide, causes persistent inflammation in the digestive tract that manifests as severe diarrhea, abdominal pain, and exhaustion. Current anti-inflammatory drugs and immune-targeting therapies help some patients, but many see little improvement or eventually become resistant to treatment.
The research team created a more accurate model for testing new drugs by growing human intestinal tissue from stem cells and then exposing it to a major inflammatory protein known to drive disease in actual patients. This approach allowed them to rapidly test approximately 3,500 compounds without relying solely on animal models.
Glycyrrhizin significantly reduced cell death in the lab-grown intestinal tissue. When the team tested the compound in mice with IBD, similar protective effects emerged, with lower inflammation levels and reduced intestinal damage compared to untreated animals.
Earlier research had hinted at glycyrrhizin's potential benefits in cellular and animal models, but this new study provides stronger evidence of its protective mechanism. The findings were published in Stem Cell Reports.
Moving from promising lab results to actual patient treatments requires careful scrutiny. Researchers acknowledge that clinical trials will be necessary to confirm whether glycyrrhizin can safely and effectively treat IBD in humans without triggering unwanted side effects. The compound's effects remain preliminary, and the path from bench to bedside typically spans years or longer.
The bigger picture here is methodological. Stem cell-derived intestinal models appear poised to accelerate drug discovery for IBD by creating a more realistic testing system than traditional approaches. If this model proves reliable, researchers could identify and validate new treatment options much faster than current methods allow.
Author Jessica Williams: "A licorice extract protecting damaged guts sounds almost too neat, but the science checks out so far, and for a disease that leaves millions frustrated with their current options, even small steps forward matter."
Comments